UBS AM’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-21,549
| Closed | -$241K | – | 2646 |
|
|
2017
Q3 | $241K | Buy |
21,549
+10,252
| +91% | +$113K | ﹤0.01% | 2167 |
|
|
2017
Q2 | $124K | Hold |
11,297
| – | – | ﹤0.01% | 2320 |
|
|
2017
Q1 | $111K | Hold |
11,297
| – | – | ﹤0.01% | 2290 |
|
|
2016
Q4 | $122K | Sell |
11,297
-22,800
| -67% | -$228K | ﹤0.01% | 2218 |
|
|
2016
Q3 | $349K | Hold |
34,097
| – | – | ﹤0.01% | 2183 |
|
|
2016
Q2 | $445K | Hold |
34,097
| – | – | ﹤0.01% | 2016 |
|
|
2016
Q1 | $375K | Sell |
34,097
-3,000
| -8% | -$26.7K | ﹤0.01% | 2092 |
|
|
2015
Q4 | $341K | Hold |
37,097
| – | – | ﹤0.01% | 2278 |
|
|
2015
Q3 | $257K | Hold |
37,097
| – | – | ﹤0.01% | 2376 |
|
|
2015
Q2 | $364K | Buy |
37,097
+6,800
| +22% | +$61.9K | ﹤0.01% | 2245 |
|
|
2015
Q1 | $268K | Buy |
30,297
+1,100
| +4% | +$8.76K | ﹤0.01% | 2330 |
|
|
2014
Q4 | $256K | Buy |
29,197
+3,000
| +11% | +$24.3K | ﹤0.01% | 2329 |
|
|
2014
Q3 | $180K | Hold |
26,197
| – | – | ﹤0.01% | 2412 |
|
|
2014
Q2 | $138K | Hold |
26,197
| – | – | ﹤0.01% | 2497 |
|
|
2014
Q1 | $119K | Hold |
26,197
| – | – | ﹤0.01% | 2531 |
|
|
2013
Q4 | $132K | Hold |
26,197
| – | – | ﹤0.01% | 2473 |
|
|
2013
Q3 | $133K | Hold |
26,197
| – | – | ﹤0.01% | 2421 |
|
|
2013
Q2 | $130K | Buy |
+26,197
| New | +$125K | ﹤0.01% | 2358 |
|
UBS AM's SCLN Position: Q4 2017 in Review
UBS AM sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 21,549 shares — an estimated $241K sold.
UBS AM first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $445K in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- UBS AM reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- UBS AM sold 21,549 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $241K.
- UBS AM first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- UBS AM's Sciclone Pharmaceuticals Inc position peaked at $445K in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on UBS AM's 13F filing for Q4 2017, filed 9 Feb 2018.